Meningitis outbreak prompts warnings, recalls
Share with others:
WASHINGTON -- More than 17,000 vials of an injectable steroid that has been linked to 35 cases of meningitis, five of them fatal, were sent to doctors' offices and clinics in 23 states, including Pennsylvania, over the summer, health officials said Thursday.
How many of the vials remain unused isn't known. All have been recalled and the Massachusetts pharmacy that made them has stopped shipping all products, the officials said.
Fungus in some of the vials appears to have caused a rare brain infection that requires months of intravenous antibiotics to cure. Federal health authorities have asked physicians to contact every patient who may have received the drug from three contaminated lots.
"Despite the current recall we expect to see additional cases," Benjamin Park, a physician at the Centers for Disease Control and Prevention, told reporters. "It is possible that if patients are identified soon and started on antifungal therapy some of the unfortunate consequences may be averted."
The medicine, methylprednisolone acetate, is injected around the spinal cord in the lower back to relieve pain caused by ruptured disks or spinal stenosis. It gains access to the brain through a water-like substance called cerebrospinal fluid.
Symptoms of meningitis sometimes take one to four weeks to appear. They include fever, headache, nausea and stroke-like weakness.
The drug was made by New England Compounding Center of Framingham, Mass., west of Boston. Little could be learned about the company Thursday. Its website was down; a call seeking to speak to someone there was not returned.
"Compounding pharmacies" are essentially boutique drug companies. They custom-make medicines for individual patients. The products are usually drug formulations not available through conventional pharmaceutical manufacturers in the dose or quantity needed.
Of the country's 56,000 community pharmacies, 7,500 are compounding pharmacies, and 3,000 make sterile products, said David Miller, head of the International Academy of Compounding Pharmacists, in Houston.
Mr. Miller said national distribution of a common drug in large quantities is distinctly uncommon.
"This does not look like traditional pharmacy compounding at all," he said.
Six states, including Maryland and Virginia, have reported cases. Tennessee, where the first case was identified on Sept. 28, has 25 cases and three deaths.
In Pennsylvania, the Department of Health confirmed that no cases have been reported in the commonwealth, but that it is working with two pain clinics to identify and contact patients who received the suspected medication. One of those clinics is South Hills Pain and Rehab Associates, with locations in Jefferson Hills, Bethel Park, Monessen and Brentwood. The other is Allegheny Pain Management in Altoona.
The clinics in Pennsylvania are no longer using the medication from the Massachusetts pharmacy, the health department said.
Massachusetts officials said the three suspect lots of methylprednisolone contained 17,676 single-use vials. They were shipped from July through September.
How many different products New England Compounding Center makes wasn't clear, but the officials said it was at least a dozen. Food and Drug Administration officials advised physicians to use no products made by the company.
Precise identification of the fungus is in the works, but in one case it was found to be Aspergillus, a type found on decaying vegetation, hay and stored grain.
Ilisa Bernstein, of the office of compliance at the Food and Drug Administration, said inspectors who visited the Massachusetts company last week found a sealed vial whose contents contained microscopic amounts of fungus.
Madeleine Biondolillo, director of the Bureau of Healthcare Safety at the Massachusetts Department of Public Health, said the state's Board of Registration in Pharmacy had received complaints "related to sterile compounding procedures" at the company in 2002 and 2003. Inspections and negotiations led to a consent decree, the details of which were not immediately available.
Another complaint last year about sterility led to an inspection but no violations were found. A fourth complaint, about the potency, not sterility, of a medicine used in eye surgery, is being investigated, she said.
First Published October 5, 2012 12:00 am